EANS-News: Semperit achieves best half-year result since the turn of the millennium in 2021 CNE

8/19/2021, 7:41 AM (Source: euro adhoc)
--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Mid Year Results

Vienna/Austria -

* Group revenue increases by 57.7% to the record level of EUR 660.8 million
* Significant revenue growth of 131.4% in the Medical Sector; Industrial Sector
  achieves revenue growth of 7.6%
* EBITDA more than quadrupled from EUR 57.6 million to EUR 247.5 million; EBITDA
  margin significantly improved to 37.5% (H1 2020: 13.7%)
* EBIT doubled to EUR 224.6 million or more than quintupled compared to adjusted
  figure in H1 2020; EBIT margin increased to 34.0% (H1 2020: 26.8%, adjusted
  10.4%)
* Adjusted free cash flow more than tripled to EUR 166.9 million

19 August 2021 - The publicly listed Semperit Group achieved a record result in
the first half of 2021 in a thoroughly challenging environment: "Despite the
increasingly inflationary raw material price trend and bottlenecks in the global
supply chains, we achieved the best half-year result since the turn of the
millennium. I am particularly pleased that this is not only due to the Medical
Sector, which continues to boom as a result of the pandemic, but also to the
good performance in our focus sector, industry," says Martin Füllenbach, CEO of
Semperit AG Holding. "Semperit has a high level of financial strength and is
therefore in a good position to take growth steps in the course of our M&A
strategy. The analysis process is in full swing; we have already taken a close
look at the first strategic acquisition opportunities."

Historic record revenue thanks to growth in both sectors

With an increase of 57.7% to EUR 660.8 million, a record value was achieved in
group-wide revenue for the first half of the year. In the Medical Sector,
revenue growth of 131.4% was again exceptionally high in view of significantly
higher sales prices in the wake of the pandemic-related special economic
situation, although sales volumes declined as a result of the limited container
availability. The 7.6% increase in revenue in the Industrial Sector, on the
other hand, is primarily due to the rise in sales volumes in the Semperflex and
Semperseal segments. Following the restructuring of the Semperit Group initiated
at the beginning of 2018, the Industrial Sector has not only demonstrated
economic resilience, especially since the beginning of the corona crisis, but
has also already recovered, as evidenced by improved order books.

Operating EBITDA improved for the 14th consecutive quarter

The record revenue result translated directly into the operating result: Group
EBITDA rose from EUR 57.6 million in the first half of 2020 to EUR 247.5 million
in the same period of 2021 - and thus more than quadrupled. "As of the reporting
date of 30 June 2021, we improved the operating EBITDA year-on-year for the
fourteenth consecutive time," Füllenbach states. The EBITDA margin was
significantly increased to 37.5% in the first half of 2021 (H1 2020: 13.7%).
Group EBIT also doubled in this period to EUR 224.6 million and the EBIT margin
increased to 34.0% (H1 2020: 26.8%). Compared with the H1 2020 EBIT adjusted for
the impairment loss and impairment reversal at EUR 43.4 million the EBIT in H1
2021 could even be quintupled while the EBIT margin more than tripled compared
with the adjusted EBIT margin of H1 2020 (10.4%).

Cash-effective investments in tangible and intangible assets at EUR 18.8 million
in the first half of 2021 were higher than the previous year's level of EUR 11.9
million. In the future, increasingly growth-oriented investments are planned
again.

Following the resolution of the Annual General Meeting on 27 April 2021, a
dividend of EUR 1.50 per share was paid out, corresponding to a dividend yield
of 6.2% at the end of 2020 at a share price of EUR 24.30. After repayment of the
pending EUR 30 million tranche of hybrid capital at the end of March, the
Semperit Group is not only in an excellent financial position (net cash surplus
including money market funds of EUR 75 million as of June 30, 2021, equity ratio
of 48.6%), but has now also improved growth options. The free cash flow adjusted
for the money market funds has more than tripled to EUR 166.9 million.

Outlook and strategic focus for 2021

Based on current figures, the Executive Board of Semperit AG Holding continues
to assume that the Group's EBITDA for the full year 2021 will be around EUR 395
million and thus significantly above the EBITDA for 2020. This earnings forecast
depends particularly on the availability of the required raw materials, the
sales prices for medical protective gloves over the course of the year and
sufficient container availability for the delivery of the Semperit Group's
products. In addition, the development of raw material and container prices are
significant factors influencing the company's results. Moreover, it is difficult
to calculate the effects in connection with the further development of the
corona pandemic and the vaccination rate, particularly due to the strongly
divergent regional trends and their influence on the international production
sites.

A noticeable recovery of the markets in the Industrial Sector is expected for
2021 - whereby the markets will develop differently according to their
cyclicality and will reflect this.

The ongoing effects of the corona pandemic continue to have a positive impact on
the price of medical products. However, the Executive Board of Semperit AG
Holding assumes that the price level will decrease over the course of the second
half of the year. This development was also considered when calculating the
expected EBITDA.

The strategic reorientation of the Semperit Group with a focus on the Industrial
Sector will continue. The strong liquidity situation ensures that the company is
also well positioned for possible M&A transactions. Work is also underway on a
more sustainable orientation of the Group based on ESG criteria.

Overview of the most important financial key figures in H1 2021

 _______________________________________________________________________
|Key figures of the Semperit Group, in   |          |        |          |
|EUR million                             |H1 2021   |Change  |H1 2020 1)|
|________________________________________|__________|________|__________|
|Revenue_________________________________|660.8_____|+57.7%__|418.9_____|
|EBITDA__________________________________|247.5_____|>100%___|57.6______|
|EBITDA_margin___________________________|37.5%_____|+23.7_PP|13.7%_____|
|EBIT_adjusted___________________________|224.6_____|>100%___|43.4______|
|EBIT_margin_adjusted____________________|34.0%_____|+23.6_PP|10.4%_____|
|EBIT____________________________________|224.6_____|>100%___|112.2_____|
|EBIT_margin_____________________________|34.0%_____|+7.2_PP_|26.8%_____|
|Earnings_after_tax_adjusted_____________|173.9_____|>100%___|23.9______|
|Earnings_after_tax______________________|173.9_____|+71.0%__|101.7_____|
|Earnings_per_share_(EPS),_in_EUR________|8.42______|+78.1%__|4.73______|
|Gross_cashflow__________________________|230.5_____|>100%___|49.6______|
|Free_cashflow___________________________|117.0_____|>100%___|47.1______|
|_______________________________________________________________________|
|Balance sheet key figures, in EUR       |          |        |          |
|million                                 |30.06.2021|Change  |31.12.2020|
|________________________________________|__________|________|__________|
|Balance_sheet_total_____________________|934.6_____|+22.3%__|764.4_____|
|Equity__________________________________|456.9_____|+36.5%__|334.6_____|
|Net_debt________________________________|-25.0_____|n.a.____|22.1______|
|Net_debt_to_EBITDA______________________|n.a.______|n.a.____|0.1_______|
|Additions to tangible and intangible    |22.0      |>100%   |10.6      |
|assets__________________________________|__________|________|__________|
|_______________________________________________________________________|
|                                        |          |        |          |
|ESG                                     |H1 2021   |Change  |H1 2020   |
|________________________________________|__________|________|__________|
|Employees_(at_balance_sheet_date)_______|6,956_____|-1.3%___|7,047_____|
|_______________________________________________________________________|
|Sector and segment key figures, in EUR  |          |        |          |
|million                                 |H1 2021   |Change  |H1 2020   |
|________________________________________|__________|________|__________|
|Industrial_Sector|Revenue_______________|268.1_____|+7.6%___|249.2_____|
|_________________|EBITDA________________|41.3______|-7.7%___|44.8______|
|_________________|EBIT__________________|29.0______|>100%___|12.2______|
|__Semperflex_____|Revenue_______________|114.4_____|+16.3%__|98.4______|
|_________________|EBITDA________________|26.2______|+12.4%__|23.3______|
|_________________|EBIT__________________|20.6______|+16.6%__|17.7______|
|__Sempertrans____|Revenue_______________|51.1______|-17.5%__|62.0______|
|_________________|EBITDA________________|1.8_______|-72.3%__|6.6_______|
|_________________|EBIT__________________|0.1_______|>100%___|-15.6_____|
|__Semperform_____|Revenue_______________|43.4______|+4.0%___|41.8______|
|_________________|EBITDA________________|6.6_______|-21.2%__|8.4_______|
|_________________|EBIT__________________|4.8_______|-27.8%__|6.6_______|
|__Semperseal_____|Revenue_______________|59.0______|+25.4%__|47.1______|
|_________________|EBITDA________________|6.6_______|+2.8%___|6.4_______|
|_________________|EBIT__________________|3.4_______|-1.2%___|3.5_______|
|Medical Sector   |Revenue               |392.7     |>100%   |169.7     |
|(Sempermed)______|______________________|__________|________|__________|
|_________________|EBITDA________________|220.5_____|>100%___|23.0______|
|_________________|EBIT__________________|210.6_____|+90.2%__|110.7_____|


1) Adjusted for the positive one-off effect from the impairment reversal in the
Sempermed segment (H1 2020: EBIT effect: EUR +88.8 million; earnings after tax
effect: EUR +94.1 million) and for the negative one-off effect of the impairment
in the Sempertrans segment (H1 2020: EBIT effect EUR -20.0 million; earnings
after tax effect: EUR -16.3 million)

For further details please refer to the half-year report 2021 of the Semperit
Group.

Further inquiry note:
Monika Riedel
Director Group Brand Management, Corporate Spokesperson
+43 676 8715 8620
monika.riedel@semperitgroup.com

Judit Helenyi
Director Investor Relations
+43 676 8715 8310
judit.helenyi@semperitgroup.com

www.semperitgroup.com

end of announcement                         euro adhoc
--------------------------------------------------------------------------------

issuer:       Semperit AG Holding
              Modecenterstrasse 22
              A-1030 Wien
phone:        +43 1 79 777-310
FAX:          +43 1 79 777-602
mail:         judit.helenyi@semperitgroup.com
WWW:          www.semperitgroup.com
ISIN:         AT0000785555
indexes:      WBI, ATX PRIME, ATX GP
stockmarkets: Wien
language:     English

EAX0002    2021-08-19/07:41

Ad-hoc-Mitteilung übermittelt durch euro adhoc.
Für den Inhalt ist der Emittent verantwortlich.